Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

Tourmaline Bio's Pacibekitug shows promise in IL-6 targeting for autoimmune diseases. Learn about its potential and ongoing trials. Read why TRML is a hold.

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced Wednesday that a Phase 3 trial for a high-dose version of its multiple sclerosis ...

Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

Organon (OGN) stock in focus as the Merck (MRK) spinoff buys rights to Biogen's (BIIB) biosimilar Tofidence, targeting ...

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...

Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, today revealed that Marketing Maven is No. 124 on its fifth annual Inc. Regionals: Pacific ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

Objective To assess outcomes in giant cell arteritis (GCA) patients during and after long-term tocilizumab (TCZ) treatment. Methods Retrospective analysis of GCA patients treated with TCZ at a single ...